RecruitingNot ApplicableNCT06891755

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3


Sponsor

Apreo Health, Inc.

Enrollment

250 participants

Start Date

Jul 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study subjects will be followed for 3 years. The main questions it aims to answer are: Is it safe? Does it work?


Eligibility

Min Age: 40 YearsMax Age: 84 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a bronchoscopy-based procedure (a procedure using a thin, flexible tube passed through the mouth into the lungs) designed to release trapped air in overinflated lungs caused by emphysema, a serious form of COPD. The goal is to help patients breathe more easily. **You may be eligible if...** - You are 40–84 years old - Your BMI is between 18 and 32 - You have completed a pulmonary rehabilitation program within the last 12 months - You have significant breathlessness (mMRC score of 2 or higher) - You can walk at least 100 meters in 6 minutes - Imaging shows severe emphysema in both lungs with a specific pattern of air trapping **You may NOT be eligible if...** - You are under 40 or over 84 years old - Your BMI is outside the 18–32 range - Your emphysema does not meet the required imaging criteria - You have not completed a pulmonary rehabilitation program recently Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEApreo BREATHE Airway Scaffold

The experimental treatment involves placement of up to 6 Apreo BREATHE Airway Scaffolds (up to 3 per lung), in a single procedure using bronchoscopy and fluoroscopy. Treatment group subjects will also receive optimal medical management (OMM).

OTHEROptimal Medical Management (OMM)

Subjects will receive optimal medical management tailored to patient needs and per standard of care and as outlined in the 2024 GOLD report. This may include smoking cessation, vaccination, long-acting bronchodilator therapy, corticosteroids (when appropriate), and participation in or maintenance of an exercise program or pulmonary rehabilitation program.


Locations(22)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Banner Health

Gilbert, Arizona, United States

University of California at Davis

Sacramento, California, United States

Mayo Clinic

Jacksonville, Florida, United States

Orlando Health

Orlando, Florida, United States

University of Chicago

Chicago, Illinois, United States

OSF St Francis Medical Center

Peoria, Illinois, United States

University of Kansas Medical Center Research Institute

Kansas City, Kansas, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

The Ohio State University

Columbus, Ohio, United States

Clinical Research Associates of Central Pennsylvania

DuBois, Pennsylvania, United States

Temple University

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Houston Methodist/Primary Critical Care

Houston, Texas, United States

Inova Health Care Services

Falls Church, Virginia, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Karl Landsteiner Institute - Klink Floridsdorf

Vienna, Austria

University Medical Center Groningen

Groningen, Netherlands

St. Bartholomew's Hospital

London, United Kingdom

Royal Brompton Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06891755


Related Trials